Table 5.
Cycloplegic Refraction Findings at the 12-Month Outcome Examination
| Overall | Total Dose of Bevacizumab Injected Into Eye Prior to 12 Months | P-Value | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >0.25mg | >0.125 to 0.25mg | >0.063 to 0.125mg | >0.031 to 0.063mg | >0.016 to 0.031mg | >0.008 to 0.016mg | >0.004 to 0.008mg | >0.002 to 0.004mg | >0 to 0.002mg | 0mg | ||||||||||||||
| N=196 Eyesa |
N=33 Eyesa |
N=26 Eyesa |
N=24 Eyesa |
N=18 Eyesa |
N=16 Eyesa |
N=17 Eyesa |
N=16 Eyesa |
N=21 Eyesa |
N=16 Eyesa |
N=9 Eyesa |
|||||||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | ||
| Cycloplegic Refraction (Spherical Equivalent) b | .09c | ||||||||||||||||||||||
| >+5.00D | 2 | 1% | 2 | 6% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | 0 | 0% | |
| >=+1.00D to <=+5.00D | 47 | 24% | 4 | 12% | 9 | 35% | 9 | 39% | 4 | 22% | 4 | 25% | 4 | 24% | 4 | 25% | 5 | 24% | 2 | 13% | 2 | 22 % | |
| >−1.00D to <+1.00D | 60 | 31% | 8 | 24% | 8 | 31% | 8 | 35% | 8 | 44% | 5 | 31% | 5 | 29% | 3 | 19% | 7 | 33% | 5 | 31% | 3 | 33 % | |
| −5.00D to <= −1.00D | 48 | 24% | 11 | 33% | 3 | 12% | 3 | 13% | 4 | 22% | 4 | 25% | 5 | 29% | 7 | 44% | 5 | 24% | 4 | 25% | 2 | 22 % | |
| <−5.00D | 23 | 12% | 7 | 21% | 4 | 15% | 3 | 13% | 2 | 11% | 2 | 13% | 2 | 12% | 2 | 13% | 1 | 5% | 0 | 0% | 0 | 0% | |
| Not Doneb | 16 | 8% | 1 | 3% | 2 | 8% | 1 | 4% | 0 | 0% | 1 | 6% | 1 | 6% | 0 | 0% | 3 | 14% | 5 | 31% | 2 | 22 % | |
| Mean (SD) | −1.31D (3.81D) | −2.48D (5.30D) | −0.73D (3.53D) | −0.50D (3.24D) | −1.31D (3.59D) | −1.58D (4.75D) | −1.46D (3.79D) | −2.04D (3.36D) | −0.74D (2.62D) | −0.86D (2.43D) | −0.09D (1.67D) | ||||||||||||
| Median Quartiles | −0.31D −2.50D, +1.13D |
−1.31D −4.88D, +0.13D |
0.00D −2.38D, +1.69D |
+0.75D −1.38D, +1.5D |
+0.19D −2.50D, +0.75D |
−0.13D −2.38D, +1.25D |
−0.25D −3.38D, +1.31D |
−1.88D −3.94D, +0.81D |
−0.25D −1.25D, +1.25D |
0.00D −2.50D, +0.50D |
0.13D −2.00D, +1.63D |
||||||||||||
| Range | −16.25D to +7.50D | −13.75D to +7.50D | −10.50D to +4.50D | −8.88D to +3.00D | −10.00D to +2.25D | −16.25D to +3.50D | −10.00D to +3.50D | −8.75D to +2.00D | −7.50D to +2.50D | −5.00D to +2.50D | −2.63D to +1.75D | ||||||||||||
CI = Confidence Interval
Percentages are not adjusted for any correlation between eyes.
a
Number of eyes initially examined at the 12-month exam. Gray text indicates doses that were previously reported (19).
b
Cycloplegic refraction analysis excludes 2 aphakic eyes, included in the tabulation under the “not done” category.
c
P-value from linear mixed model accounting for any correlation between eyes for an association between the continuous outcome and total dose as a categorical factor.